On June 25, Thermo Fisher Scientific rose 3.52% in regular trading, trading at approximately $511.09 per share, with turnover of $187 million, extending gains from the prior session.

On the news front, the Life Sciences Tools & Services sector rallied broadly, while Thermo Fisher recently secured a CDMO partnership with Nuvation Bio to manufacture the anti-cancer drug IBTROZI (taletrectinib) in the United States through its Patheon pharmaceutical services platform. Nuvation Bio completed a technology transfer and product introduction to Thermo Fisher for the production of the ROS1-positive non-small cell lung cancer therapy, with the supplemental filing to the NDA already completed. The collaboration demonstrates Thermo Fisher's expanding contract manufacturing capabilities for innovative oncology therapies.

Within the Life Sciences Tools & Services sector, Bio-Techne surged 19.39%, Tempus AI gained 4.41%, Danaher rose 3.71%, West Pharmaceutical added 2.63%, and IQVIA climbed 2.52%, reflecting broad-based sector strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)